PITPNM3 and breast carcinoma: Although the CCL18-PITPNM3 signaling pathway has not been revealed to play a role in bone metastasis of breast cancer, it remains unknown whether the anti-CCL18 antibody could be utilized for the treatment of breast cancer with bone metastasis [196].